Review
Eye (2007) 21, 1455–1463; doi:10.1038/sj.eye.6702636; published online 10 November 2006
Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration
N Bansback1, S Davis1 and J Brazier1
1Health Economics and Decision Science, ScHARR (School of Health and Related Research), University of Sheffield, Sheffield, UK
Correspondence: N Bansback, Health Economics and Decision Science, ScHARR (School of Health and Related Research), University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK. Tel: +44 114 222 0686; Fax: +44 114 222 0785. E-mail: n.j.bansback@sheffield.ac.uk
Received 12 August 2005; Accepted 2 October 2006; Published online 10 November 2006.
Abstract
Aims
To re-evaluate the cost-effectiveness of photodynamic therapy with verteporfin (Visudyne®, Novartis AG, Switzerland) in patients with predominantly classic and classic choroidal neovascularization (CNV) owing to age-related macular degeneration (AMD), using new evidence on the impact of contrast sensitivity on health status.
Method
A health economic model is used to synthesise the evidence on contrast sensitivity and treatment rates from the TAP Investigation with health state utilities and costs. Impairment of visual function is estimated using a Markov model to predict transitions between states of contrast sensitivity. Each state is associated with costs and a health state utility. Total expected costs and benefits for a cohort of patients over a defined number of cycles are calculated. The expected health state utility for each disease state was estimated using results from a study of 209 patients with AMD in Sheffield. The model includes the costs associated with treatment and monitoring in the verteporfin treatment arm and costs offset by delaying the deterioration of visual function.
Results
Beyond 3 years, the annual costs of the verteporfin arm are estimated to be less than the annual costs of the control arm, owing to the cost associated with higher blindness prevalence in the control arm. Over time, the results show that both the incremental utility and cost decreases. By 10 years, the estimated incremental cost-effectiveness is approximately £20 996 per Quality-Adjusted Life Years.
Conclusion
The results of this study suggest that the verteporfin therapy in the treatment for patients with predominantly classic and classic CNV owing to AMD is encouraging.
Keywords:
verteporfin, photodynamic therapy, age related macular degeneration, economics, cost effectiveness, costs
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy
Eye Article Response
